Drug intelligence / Profile preview

HTD2802

Development stage: Unknown
Lead developer: HighTide Therapeutics
Modality: Small Molecules

Overview

HTD2802 is an investigational drug candidate being developed by HighTide Therapeutics for the treatment of inflammatory bowel disease (IBD). As of August 2025, the drug is in Phase 1 clinical development. HighTide Therapeutics focuses on developing multifunctional, multi-targeted therapies for chronic metabolic and digestive diseases with significant unmet medical needs. While HTD2802 is a key part of the company's digestive disease pipeline, specific details regarding its molecular target, mechanism of action, and modality have not been publicly disclosed.

Beyond the preview

Go deeper on HTD2802.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HTD2802.

Explore the full profile